ErlySign, a health tech startup also known as CURO Biosciences, has raised ₹16 crores in pre-Series A funding from Ashish Kacholia.
The funds will be used to finalize clinical trials, secure CDSCO approvals, and bring ErlySign’s oral cancer detection kit to market. Additionally, the funds will support research and development, team expansion, and further patent filings.
Shubhendra Singh Thakur, CEO and Founder of ErlySign, said, “Our initial studies revealed exceptional results, achieving 100% specificity and 98.04% sensitivity. The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”
Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, CURO Biosciences develops solutions for the early detection of oral cancer. ErlySign secured an Indian patent in 2022 and a U.S. patent in 2023, underscoring its pioneering role in cancer diagnostics.
At the core of ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes using a simple, non-invasive saliva sample. ErlySign’s test kit promises a painless, affordable, and immediate alternative for early cancer detection, offering hope for timely intervention and improved survival rates.
ErlySign also plans to leverage CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes.
